Cargando…

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

BACKGROUND: Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to discri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Judson, Ian, Morden, James P, Kilburn, Lucy, Leahy, Michael, Benson, Charlotte, Bhadri, Vivek, Campbell-Hewson, Quentin, Cubedo, Ricardo, Dangoor, Adam, Fox, Lisa, Hennig, Ivo, Jarman, Katy, Joubert, Warren, Kernaghan, Sarah, López Pousa, Antonio, McNeil, Catriona, Seddon, Beatrice, Snowdon, Claire, Tattersall, Martin, Toms, Christy, Martinez Trufero, Javier, Bliss, Judith M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602919/ https://www.ncbi.nlm.nih.gov/pubmed/31160249 http://dx.doi.org/10.1016/S1470-2045(19)30215-3

Ejemplares similares

Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC)
por: Tovey, Holly, et al.
Publicado: (2015)

Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer
por: Snowdon, Claire, et al.
Publicado: (2022)

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
por: Gopinathan, Ganga, et al.
Publicado: (2022)

Conducting non-commercial international clinical trials: the ICR-CTSU experience
por: Fox, Lisa, et al.
Publicado: (2017)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
por: Brown, Nicholas, et al.
Publicado: (2016)

UK guidelines for the management of soft tissue sarcomas
por: Dangoor, Adam, et al.
Publicado: (2016)

UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)
por: Judson, Ian, et al.
Publicado: (2017)

Unsupervised Integration of Multiple Protein Disorder Predictors: The Method and Evaluation on CASP7, CASP8 and CASP9 Data
por: Zhang, Ping, et al.
Publicado: (2011)

CASP+ Practice Tests
por: Tanner, Nadean
Publicado: (2020)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Association Between a Polymorphism in CASP3 and CASP9 Genes and Ischemic Stroke
por: Lee, Bae Youl, et al.
Publicado: (2017)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma
por: Lobo, Merryl R., et al.
Publicado: (2015)

Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation
por: Lobo, Merryl R., et al.
Publicado: (2014)

Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray
por: Jiang, Wenhua, et al.
Publicado: (2017)

Casp8p41 and HIV
por: Cummins, Nathan W., et al.
Publicado: (2015)

Biological and functional relevance of CASP predictions
por: Liu, Tianyun, et al.
Publicado: (2017)

Evaluation of model refinement in CASP13
por: Read, Randy J., et al.
Publicado: (2019)

Cryo‐EM targets in CASP14
por: Cragnolini, Tristan, et al.
Publicado: (2021)

Role of environmental specificity in CASP results
por: Roterman, Irena, et al.
Publicado: (2023)

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
por: Fallowfield, L J, et al.
Publicado: (2012)

An analysis and evaluation of the WeFold collaborative for protein structure prediction and its pipelines in CASP11 and CASP12
por: Keasar, Chen, et al.
Publicado: (2018)

Testis cell pyroptosis mediated by CASP1 and CASP4: possible sertoli cell-only syndrome pathogenesis
por: Liu, Wantao, et al.
Publicado: (2023)

Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
por: Drazin, Doniel, et al.
Publicado: (2016)

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial
por: Stark, Dan P., et al.
Publicado: (2017)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Evaluation of template‐based modeling in CASP13
por: Croll, Tristan I., et al.
Publicado: (2019)

Applying and improving AlphaFold at CASP14
por: Jumper, John, et al.
Publicado: (2021)

Rare mutations in apoptosis related genes APAF1, CASP9, and CASP3 contribute to human neural tube defects
por: Zhou, Xiangyu, et al.
Publicado: (2018)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab
por: Suffredini, Dante A., et al.
Publicado: (2018)

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
por: Backen, Alison C., et al.
Publicado: (2018)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

Analysis techniques in the presence of non-proportional hazards (PH); application to an ovarian cancer RCT with long-term follow-up
por: Morden, James, et al.
Publicado: (2015)

Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms
por: Malik, Ihtisham, et al.
Publicado: (2015)

Evaluation of 3D-Jury on CASP7 models
por: Kaján, László, et al.
Publicado: (2007)

Therapeutic potential of HIV protease-activable CASP3
por: Miyauchi, Kosuke, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b6akdek4t9o6r0rehqqpqcjp2d